Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    RGX-202

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Regenxbio Gene Therapy Passes Interim Test As Pivotal Data Loom
    Regenxbio Gene Therapy Passes Interim Test As Pivotal Data Loom

    12 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/regenxbio-posts-clean-safety-profile-dmd-gene-therapy-pivotal-data-loom

    FIERCE BIOTECH
    12 Mar 2026
    Share Share
    Regenxbio Unveils Positive Interim Data from RGX-202 Phase I/II
    Regenxbio Unveils Positive Interim Data from RGX-202 Phase I/II

    11 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-reports-new-positive-interim-data-from-phase-iii-affinity-duchenne-trial-of-rgx-202-302711193.html

    PR NEWSWIRE
    11 Mar 2026
    Share Share
    REGENXBIO Presents At 2026 (MDA) Clinical & Scientific Conference
    REGENXBIO Presents At 2026 (MDA) Clinical & Scientific Conference

    04 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2026-muscular-dystrophy-association-mda-clinical--scientific-conference-302703477.html

    PR NEWSWIRE
    04 Mar 2026
    Share Share
    REGENXBIO Completes Pivotal Enrollment, Duchenne Gene Therapy
    REGENXBIO Completes Pivotal Enrollment, Duchenne Gene Therapy

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-completion-of-pivotal-enrollment-and-initiates-commercial-production-in-duchenne-gene-therapy-program-302599520.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    Regenxbio Announces Presentation At The World Muscle Society
    Regenxbio Announces Presentation At The World Muscle Society

    29 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-world-muscle-society-302569161.html

    PR NEWSWIRE
    29 Sep 2025
    Share Share
    Regenxbio Shows Benefits of Microdystrophin in Duchenne Gene
    Regenxbio Shows Benefits of Microdystrophin in Duchenne Gene

    11 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenxbio-announces-publication-of-preclinical-results-demonstrating-functional-benefits-of-novel-microdystrophin-construct-in-rgx-202-investigational-gene-therapy-for-duchenne-muscular-dystrophy-302502606.html

    PR NEWSWIRE
    11 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.